Pfizer, Ranbaxy sued again on alleged Lipitor delay; Cadence recalls one lot of Ofirmev injection;

@FiercePharma: Big Pharma needs to enroll at Hogwarts, the FT says. Article | Follow @FiercePharma

> A union health and welfare plan is suing Pfizer ($PFE) and Ranbaxy Laboratories, alleging the drugmakers worked together to delay generic versions of the cholesterol drug Lipitor. Report

> Cadence Pharmaceuticals ($CADX) is recalling one lot of Ofirmev injection after a unidentified particle was found in one of the vials. News

> HIV drugs used to treat children do not appear to increase their risk of developing psychiatric problems, researchers said. More

> Perrigo ($PRGO) profits beat expectations as strong sales of new products helped boost revenues. News

> Jefferies analysts raised their price target on Amylin Pharmaceuticals ($AMLN) to $30 from $25, citing upside to its sales estimates for Byetta and newly approved Bydureon. Report

> Japan's Asahi Kasei Pharma asked regulators in that country to approve Famvir, marketed under an agreement with with Novartis ($NVS), as a treatment for herpes simplex. Article

> Pfizer's Indian unit has decided to spin off an animal healthcare unit for $89.7 million. Story

> Executives of Efroze Chemicals, under investigation in Pakistan after more than 100 patients died while using suspect medicines, have been put on the Exit Control List to keep them from leaving the country. Report

> Takeda Pharmaceuticals launched its blood pressure combo pill Edarbyclor, which comprises an angiotensin receptor blocker and chlorthalidone, in the U.S. Release

Biotech News

@FierceBiotech: GSK will cut 3 research units, add 4 as R&D productivity swells. Witty pronounced himself satisfied. Article | Follow @FierceBiotech

@JohnCFierce: GSK completes tally on DPUs: 3 gone, 4 added, 8 get new chiefs. Productivity up. Seem pretty happy with the direction. News | Follow @JohnCFierce

@FierceMedDev: Consumers Union pushes to improve medical device safety: Story | Follow @FierceMedDev

> Merck tracks positive results, bleeding risk in second big vorapaxar study. News

> Orexigen surges on FDA trial pact for troubled weight loss drug. Article

Manufacturing News

> FDA report shows deep problems at closed Novartis Consumer Health plant. More

> Merck's manufacturing information not trade secrets, court rules. News

> AstraZeneca faces resistance to job cuts on home turf. Story

> Dishman set to bail on API manufacturing in once-promising China. Article

> Smith & Nephew eliminating 800 jobs, restructuring already felt in Memphis. News

Research News

> CA stem cell researchers planning for life without state funding. Item

> In a breakthrough, scientists blame tau proteins for spreading Alzheimer's. More

> Silver, slayer of werewolves, explored as cancer fighter. Article

> Walnuts slow prostate cancer tumor growth in mice. Story

> Can't get enough donuts? A specific gene variation may explain why. More

And Finally... Canine cancer trials could advance personalized medicine. Article

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in non-diabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.